NCT05917106

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 450 (estimated)
• Sponsor: Jinling Hospital, China · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

Detailed description

Some studies have shown the potential of ctDNA in renal cancer monitoring, but the amount of ctDNA released in renal cancer is the lowest among non-cranial tumors. Even in advanced patients, the detection rate of tumor system mutation is less than 50%. DNA methylation is important in the process of tumor occurrence and development. However, no studies have focused on the value of ctDNA methylation in monitoring renal cancer, nor have large prospective cohort studies been conducted in patients with renal cancer. This study intended to analyze the dynamic changes of circulating tumor DNA and its methylation status in patients with kidney cancer from preoperative to long-term follow-up, and to compare the evaluation value of methylation detection with traditional imaging examination and traditional blood tumor markers in the monitoring process.

Conditions

• Carcinoma
• Renal Cell Carcinoma
• RCC
• Kidney Neoplasms
• Kidney Cancer

Timeline

• Start date: 2022-12-26
• Primary completion: 2028-06-01
• Completion: 2030-06-01
• First posted: 2023-06-23
• Last updated: 2025-12-11

Locations

1 site across 1 country: China